Time to resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Resolution of symptoms · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) · any patient population and people with high cardiovascular risk
Colchicine showed no clear difference in mortality (all‐cause) compared with any control treatment (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · any patient population and people with high cardiovascular risk
Colchicine showed no clear difference in mortality (cardiovascular) compared with any control treatment (moderate certainty).
1 finding from 1 review
Myocardial infarction · any patient population and people with high cardiovascular risk
Colchicine probably leads to lower myocardial Infarction (total) compared with any control treatment (moderate certainty).
1 finding from 1 review
Adverse event (total) · any patient population and people with high cardiovascular risk
It is very uncertain whether colchicine changes adverse event (total) compared with any control treatment (very low certainty).
1 finding from 1 review
Gastrointestinal adverse events · any patient population and people with high cardiovascular risk
Colchicine may leads to higher adverse event (gastrointestinal) compared with any control treatment (low certainty).
1 finding from 1 review
Adverse event (serious) · any patient population and people with high cardiovascular risk
1 finding from 1 review
Heart failure · any patient population and people with high cardiovascular risk
Colchicine showed no clear difference in heart failure (total) compared with any control treatment (low certainty).
1 finding from 1 review
Stroke · any patient population and people with high cardiovascular risk
Colchicine showed no clear difference in stroke (total) compared with any control treatment (low certainty).
1 finding from 1 review
Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether colchicine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether colchicine changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found